MeSH Browser

MeSH Heading: Antineoplastic Agents, Hormonal
Tree Number(s): D27.505.954.248.169
Unique ID: D018931
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D018931
Annotation: consider also NEOPLASMS, HORMONE-DEPENDENT /‌drug ther
Scope Note: Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Entry Version: ANTINEOPL AGENTS HORMONAL
Entry Term(s): Antineoplastic Drugs, Hormonal; Antineoplastic Hormonal Agents; Antineoplastic Hormonal Drugs; Antineoplastics, Hormonal; Hormonal Agents, Antineoplastic; Hormonal Antineoplastic Agents; Hormonal Antineoplastic Drugs; Hormonal Antineoplastics
Previous Indexing: Antineoplastic Agents (1966-1995)
Public MeSH Note: 96
History Note: 96
Date Established: 1996/01/01
Date of Entry: 1995/05/26
Revision Date: 2005/06/30

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analysis (AN)

antagonists & inhibitors (AI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

economics (EC)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Chemical Actions and Uses [D27]
- Pharmacologic Actions [D27.505]
  - Therapeutic Uses [D27.505.954]
    - Antineoplastic Agents [D27.505.954.248]

Antineoplastic Agents, Hormonal Preferred

Concept UI: M0028300
Scope Note: Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Terms: Antineoplastic Agents, Hormonal Preferred Term
Term UI T056421
Date01/01/1999
LexicalTag NON
ThesaurusID NLM (1996); Hormonal Agents, Antineoplastic
Term UI T056419
Date03/21/1995
LexicalTag NON
ThesaurusID NLM (1996); Hormonal Antineoplastic Agents
Term UI T056420
Date10/24/1994
LexicalTag NON
ThesaurusID NLM (1996); Antineoplastic Drugs, Hormonal
Term UI T056422
Date11/30/1994
LexicalTag NON
ThesaurusID NLM (1996); Antineoplastic Hormonal Drugs
Term UI T056423
Date03/21/1995
LexicalTag NON
ThesaurusID NLM (1996); Hormonal Antineoplastic Drugs
Term UI T056424
Date11/30/1994
LexicalTag NON
ThesaurusID NLM (1996); Antineoplastics, Hormonal
Term UI T056425
Date10/31/1994
LexicalTag NON
ThesaurusID NLM (1996); Antineoplastic Hormonal Agents
Term UI T056418
Date03/21/1995
LexicalTag NON
ThesaurusID NLM (1996); Hormonal Antineoplastics
Term UI T056426
Date01/22/1995
LexicalTag NON
ThesaurusID NLM (1996)

Antineoplastic Agents, Hormonal MeSH Descriptor Data 2025